Details

Autor(en) / Beteiligte

• Zeuzem, Stefan
• Dusheiko, Geoffrey M
• Salupere, Riina
• Mangia, Alessandra
• Flisiak, Robert
• Hyland, Robert H
• Illeperuma, Ari
• Svarovskaia, Evguenia
• Brainard, Diana M
• Symonds, William T
• Subramanian, G. Mani
• McHutchison, John G
• Weiland, Ola
• Reesink, Hendrik W
• Ferenci, Peter
• Hézode, Christophe
• Esteban, Rafael

Titel

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

Ist Teil von

• The New England journal of medicine, 2014-05, Vol.370 (21), p.1993-2001

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Link zum Volltext

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• In patients with HCV genotypes 2 and 3, sofosbuvir plus ribavirin was administered for 12 weeks in patients with genotype 2 and for 24 weeks in those with genotype 3. Rates of sustained virologic response were 93% in patients with genotype 2 and 85% in those with genotype 3. Of the six main genotypes of the hepatitis C virus (HCV), genotypes 2 and 3 account for approximately 30% of chronic infections worldwide. 1 Although these two genotypes have historically been grouped together in treatment guidelines and clinical trials, 2 , 3 accumulating evidence suggests that there are important clinical differences between them. 1 , 4 , 5 HCV genotype 3 infection is associated with a higher incidence of hepatic steatosis, more rapid progression of fibrosis, and possibly a greater risk of hepatocellular carcinoma than is HCV genotype 2 infection. 6 Moreover, patients with HCV genotype 3 infection are less responsive to peginterferon-based treatment than are patients . . .